London cyber and medtech crossing into the US: where the commercial frame breaks.

The London cyber and medtech landscape.

London carries two of the densest commercial clusters in Europe for the categories this note addresses. The London cyber cluster sits across the City of London, Whitechapel, King's Cross, and Canary Wharf, with a gravitational pull toward UK financial-services customers, UK government customers, and European enterprise buyers. The cluster has been shaped over fifteen years by a combination of UK government procurement, NCSC-adjacent capability frameworks, the post-2015 UK cyber strategy, and the migration of US and European talent into London as a European commercial base. London medtech sits across a wider geography: the London teaching-hospital belt, the Cambridge biomedical cluster, the Oxford life-science ecosystem, and the academic-industrial overlap between University College London, Imperial, King's, and the Francis Crick Institute. The medtech cluster has been shaped by the NHS as a procurement and reference architecture, the MHRA as the regulatory anchor, NIHR as the clinical-research framework, and the London-Cambridge-Oxford academic triangle as the innovation source.

Both clusters produce firms that arrive at US market entry with genuinely strong home-market proof. A London cyber firm crossing the Atlantic typically carries NCSC-aligned capability language, UK financial-services customers, UK government contracts (often including Ministry of Defence, Home Office, or intelligence-community work that cannot be disclosed publicly), UK law-enforcement engagements, and FTSE-listed enterprise references. A London medtech firm carries MHRA clearance or approval, NHS Trust customers, NIHR-sponsored clinical research, UK health-economic evidence, Oxbridge or UCL academic partnerships, and UK KOL endorsements. The home-market materials are clean, credible, and accurate. The question is not whether the firm has a position. The question is whether the US-facing presentation of that position is built in the register the American buyer filters on.

A consistent pattern emerges. Firms that have spent ten or fifteen years building UK commercial authority, often underpinned by UK government work, arrive in the US expecting the same proof stack to carry. The US federal buyer and the US Fortune 500 buyer, and in medtech the US hospital system, US payer, and US KOL, each filter on US-side proof architecture. The UK government references are recognised as high-quality but are read as non-transferable. The UK commercial references sit outside the US peer set. The UK KOL endorsements carry context but do not substitute for US-side relationships. The first ninety days of US activity go slower than planned.

What UK government references signal at home, and what US commercial buyers actually filter on.

UK government references are high-bar trust signals inside the UK frame. NCSC-aligned posture, NIHR trial participation, MHRA clearance, NHS Trust customer status, and UK public-sector contracts each signal that a sovereign-grade evaluator has assessed the firm and found it credible. Inside the UK commercial frame these signals often stand on their own. A UK Fortune 100 CISO or a UK health system reads NCSC-aligned or NIHR-anchored posture and receives the signal as validation. The evaluation shortcut works because the reader and the evaluator operate inside the same sovereign context.

The US reader does not share the context. The US federal buyer operates inside the US federal procurement system, with its own certification and accreditation architecture (FedRAMP, CMMC, StateRAMP, FISMA, ATO readiness, FCL and personnel-cleared staffing, US federal-side past-performance records, SBIR and OTA vehicles). The US Fortune 500 CISO operates inside a peer-reference frame dominated by US Fortune 500 customers and US Gartner or Forrester peer evaluations. The US hospital-system evaluator, the US GPO decision-maker, the US payer-review committee, and the US KOL each operate inside their own US-specific reference frames. None of these readers is dismissive of UK government proof. All of them are filtering on a US-side proof stack that the UK references do not directly populate.

The consequence is predictable. A UK cyber firm leading a US federal conversation with NCSC-aligned capability language and UK MoD references is asking the US federal reader to translate the UK posture into US certification and accreditation status. The reader does not perform the translation. A UK medtech firm arriving at a US hospital system with MHRA clearance and UK NIHR endorsement is asking the US procurement officer to translate the UK regulatory and clinical framework into US FDA and US reimbursement equivalents. The officer does not perform the translation. The UK proof stays in the supporting layer. The US proof has to be built in front of it.

The UK government reference is not the problem. The problem is leading with it. The US buyer needs the US commercial frame in front, with UK government proof held as supporting trust below. House view on London cyber and medtech US entry

Three signal gaps for cyber specifically.

US federal proof architecture absent. The US federal cyber buyer filters on a specific proof stack: FedRAMP moderate or high authorisation, CMMC Level 2 or 3 posture, FISMA compliance trajectory, ATO status with named agencies, FCL (Facility Clearance Level) and cleared-personnel staffing, named US federal past-performance, and vehicle readiness (GSA schedules, SEWP, CIO-SP4, OTA eligibility). UK cyber firms arriving with NCSC-aligned language, UK MoD references, and Cyber Essentials Plus posture are presenting proof the US federal reader recognises as high-quality and non-qualifying. The correction is the construction of a US federal proof architecture on the US-facing surface: a statement of US federal posture, a named path toward FedRAMP or CMMC as relevant, and named US federal pilot relationships or cleared-personnel structure where they exist. The US federal conversation does not start without the US federal frame in place.

Fortune 500 peer-set missing. The US Fortune 500 CISO buys cyber against a peer reference frame. Peers are US Fortune 500 customers in the same or adjacent sectors. Proof points are US-case studies, US Gartner or Forrester positioning, US-case peer quotes, US-side board advisors, and US commercial-scale deployments. UK cyber firms leading with FTSE references and UK financial-services case studies are making a proof claim the US Fortune 500 CISO cannot apply. The FTSE references are recognised as strong and non-indexable. The correction rebuilds the US-facing peer set: US Fortune 500 customers where they exist, US Fortune 500 advisory relationships where they do not, US-side analyst recognition, US-side board positions, and US case materials written in the US commercial register. The UK references move to supporting proof.

Commercial-not-government framing missing. UK cyber firms whose home identity is anchored in UK government work often extend the government register into the US-facing materials. The government-facing register is correct for US federal conversations and wrong for US commercial conversations. The US Fortune 500 CISO, the US enterprise buyer, and the US commercial partner are not the US federal buyer. They filter on commercial outcomes, commercial reference architecture, commercial-scale deployments, and commercial-register language. The UK firm that presents identical materials to US federal and US Fortune 500 audiences is converting one or the other by accident. The correction splits the US-facing surface: a federal-facing frame for US federal conversations, a commercial-facing frame for US enterprise conversations, each built around the proof architecture the specific US reader filters on.

Three signal gaps for medtech specifically.

FDA posture unclear. US hospital systems, US GPOs, US payers, US physician buyers, and US health-system evaluators filter first on FDA clearance or approval status and the US regulatory trajectory. 510(k), De Novo, PMA, Breakthrough Device, and IDE pathway status each produce different US commercial motions. UK medtech firms arriving with MHRA posture as the lead proof are making a regulatory claim the US reader cannot apply. MHRA clearance is recognised as credible and does not index against US FDA posture. The correction is the statement of FDA posture on the front of every US-facing surface: the device class, the US regulatory pathway, the current status (cleared, submitted, planned), and the named path toward US clearance if not already in place. MHRA and EU posture move to the supporting layer.

US payer framing absent. US payers, including CMS for Medicare and Medicaid and the major commercial payers, filter on US reimbursement precedent, US coverage pathway (CPT and HCPCS coding, NCD and LCD posture, DRG positioning where relevant), US health-economic evidence structured for US payer review, and US clinical-outcome endpoints that match US payer evaluation frames. UK medtech firms arriving with strong UK NICE-aligned health-economic evidence and UK reimbursement precedent are making a case the US payer cannot directly apply. The correction constructs the US payer frame explicitly: US coverage pathway mapped, US coding positioning described, US health-economic evidence rebuilt for US payer review, and US clinical-outcome endpoints named. The UK health-economic evidence stays in the supporting stack. The US payer frame sits in the lead.

US KOL referenceability missing. US KOLs in a therapeutic area filter on US-side investigator relationships, US-site clinical activity, US publication presence in the journals the US KOL community pays attention to, US-society participation, and US peer-of-peer endorsements. UK medtech firms arriving with UK KOL endorsements, NIHR-anchored clinical work, and UK-led publications are presenting KOL proof the US KOL recognises as high-quality and non-qualifying. The US KOL cannot endorse a firm whose US-side proof stack is empty, because the endorsement would not carry weight with US peer KOLs who are themselves filtering on US-side proof. The correction constructs the US KOL referenceability layer: US-side investigator relationships established (often through US pilot positions, US-site clinical activity, or US-tier advisory relationships), US clinical-site activity named, US publication presence built through US-KOL co-authorship, and US society participation active. The UK KOL endorsements stay as supporting trust.

The engineering-commercial translation problem inside both verticals.

Cyber and medtech share a structural tendency: both are engineer-led categories where the product, the clinical evidence, and the technical architecture are genuinely strong and the commercial materials often read as technical specification rather than commercial positioning. The specification is accurate. The specification is, in the home audience, often the correct commercial presentation because the UK and European technical buyer values specification as trust. The US commercial buyer, whether a US Fortune 500 CISO, a US hospital-system procurement officer, a US payer, a US GPO, or a US commercial partner, is not the technical evaluator inside their organisation. The US commercial buyer is the decision-maker who authorises the technical evaluation. The commercial buyer filters on the commercial frame first. The technical detail supports the commercial decision; it does not replace it.

The failure mode is predictable. A London cyber firm arrives at a US Fortune 500 CISO conversation with a deck that opens on detection architecture, threat-model coverage, detection-and-response engineering, and technical certification. The content is strong. The CISO is looking at the deck in the first ninety seconds for a commercial frame: the category the firm sits inside, the US customer peer set, the US commercial outcome the firm produces, and the US-scale deployment proof. The deck does not lead there. A London medtech firm arrives at a US hospital-system procurement conversation with a deck that opens on clinical specification, trial-design rigour, and regulatory pathway detail. The procurement officer is looking for the US category, the US customer type, the US outcome in hospital-system terms (reduced length of stay, reduced readmission rate, reduced cost per episode, improved quality metrics, named US-facility pilot), and the US payer pathway. The deck does not lead there either.

The correction is architectural rather than tonal. Softening the specification language does not solve the problem. Moving the commercial frame to the front does. The technical and clinical detail remains exactly as rigorous, one layer below the commercial claim the US reader needs in the lead position. Engineer-led London firms often resist this move because the technical and clinical specifications are where the firm's hard-won expertise sits and the instinct is to lead with the expertise. The resistance is understandable. The US commercial buyer does not need the firm to lead with the expertise. The US commercial buyer needs the firm to lead with the commercial claim, then prove it with the expertise beneath. Done correctly, the move does not soften the firm's authority; it surfaces it in a register the US commercial reader evaluates.

The fix sequence.

Three stages in order. The order matters. Rebuilding materials on a broken frame produces cleaner execution on the same misread.

Diagnose. The first stage identifies which of the signal gaps is breaking first in the specific firm's US-facing frame. A London cyber firm at the first US federal pilot stage with no FedRAMP path has a different first break than a London cyber firm at the first US Fortune 500 CISO conversation with no US peer set. A London medtech firm at the first US hospital-system conversation with unclear FDA posture has a different first break than a London medtech firm at the first US payer meeting with no US health-economic framing. The diagnosis surfaces where the US conversations are going quiet, what US readers are encountering in the first ninety seconds of the materials, and which of the gaps is doing the damage.

Correct the signal. The second stage rebuilds the US-facing frame. For cyber this means constructing US federal proof architecture where federal is the target, building a US Fortune 500 peer set where commercial is the target, and splitting the US-facing surface into federal-facing and commercial-facing frames where both are in play. For medtech this means stating FDA posture at the front, constructing US payer framing as a first-class deliverable, and building US KOL referenceability through US-side investigator relationships and US clinical-site activity. In both verticals the UK government proof moves from the lead to the supporting stack. The commercial claim moves to the front. The engineering and clinical detail moves one layer below the commercial claim.

Rebuild the execution layer. The third stage rebuilds the surfaces the US reader encounters. For cyber: US federal-targeted materials, US Fortune 500 commercial decks, US-case study library, US-side principal bios rebuilt for the US peer set, US-facing site architecture, and the US commercial cadence of the US-facing team. For medtech: US hospital-system decks, US payer-facing health-economic materials, US-KOL-facing materials, US clinical-site and investigator materials, US-side principal bios, and the US commercial cadence. The execution layer sits on top of the corrected frame. Done last, it produces materials that survive the US filter. Done first, it produces well-executed materials that repeat the original misread with higher fidelity.

When to engage us.

The firm runs three engagements for London cyber and medtech principals entering the US. Fit and pricing are confirmed in discovery, not published.

• Market Entry Sprint (six to ten weeks) for a single US category correction and the first US-facing materials rebuilt and shipped. Typical for a London cyber firm at the first US federal pilot or first US Fortune 500 CISO conversation, or a London medtech firm at the first US hospital-system or US payer meeting. See the Sprint →
• Cross-Border Build (three to six months) for a full US rebuild across positioning, US federal and US commercial materials for cyber, US hospital-system and US payer materials for medtech, US-side principal bios, US-facing site, and US commercial cadence. Standard shape for London cyber and medtech firms committed to US commercialisation. See the Build →
• Group Partnership (monthly retainer, twelve-month minimum) for London family-office-backed holdings with multiple cyber or medtech operating companies requiring US-facing rebuilds in parallel. See the Partnership →

For the wider London corridor gate, see the London city page. For the operators page inside the London corridor, see the London operators page. For the sibling problem on UK-to-US brand reception, see UK brand in US market reception.

Frequently asked questions.